Australian research finds vaccine patch may fight COVID-19 better than injection

studies in ratspublished inVaccine Journal (Vaccine) on Thursday (28 July) found that patch vaccineThe type that uses technology to increase the stability ofspiny proteinof infectionnew coronavirus or Hexa Pro (Hexapro) is effective in fighting the virus.Covid-19 speciesOmikron Up to 11 times as compared to the same vaccine administered by needle.

Dr Chris McMillan, Research Fellow at the University of Queensland’s Institute of Chemistry and Molecular Biology, said: vaccine patchcontaininghigh density micro needle (microarray patch) will be able to deliver the vaccine precisely into the skin layer rich in immune cells.

– Hexapro vaccine patch (photo credit: University of Queensland) –

Hexapro vaccine patch which was developed by the University of Queensland in collaboration with wax (Vaxxas) A biotech startup in Brisbane willIntradermal vaccines are delivered through thousands of tiny needles.

during the experiment The researchers gave the hexapro vaccine either as a syringe or patch to eight mice, before testing their blood on several COVID-19 samples, including a line subspecies. Alpha, Delta and Omikron

The results showed that The patch vaccine provokes a strong immune response and is effective against germs.covid virus whole speciesOmikronanddelta higher than the syringe vaccine

Dr David Muller, one of the researchers at the University of Queensland, said the findings provide preliminary evidence that the patch vaccine may help combat the growing number of mutations. This is difficult for existing vaccines to prove.

Muller said The reduced efficacy of currently available vaccines is evident from the Omikron strain. It can mutate in more than 30 locations on the spiny protein, and that it’s important to remember that Existing syringe vaccines remain an effective way to prevent severe symptoms of COVID-19.

However, technologyvaccine patchwill increase accessibilityVaccines against COVID-19 and other vaccines in the future because they canEasy to transport and use as well as being able to maintain stability at room temperature for up to 30 days

Mr David Hoey, Chief Executive Officer (CEO) ofwax It said the company is now scaling up production as the vaccine enters large-scale clinical trials. before being introduced into the commercial market. The company will establish its first production facility in Brisbane. to support the transition to commercial vaccines

——–

Source: Xinhua, University of Queensland

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.